{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:03:40Z","timestamp":1745827420803},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T00:00:00Z","timestamp":1350950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11523-012-0235-8","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T10:06:34Z","timestamp":1350900394000},"page":"247-251","source":"Crossref","is-referenced-by-count":18,"title":["Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma"],"prefix":"10.1007","volume":"7","author":[{"given":"Thomas","family":"Neuhaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Luyken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,23]]},"reference":[{"issue":"Suppl 4","key":"235_CR1","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","volume":"5","author":"EA Engels","year":"2010","unstructured":"Engels EA (2010) Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5(Suppl 4):S260\u2013S265","journal-title":"J Thorac Oncol"},{"key":"235_CR2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1378\/chest.127.3.755","volume":"127","author":"DJ Kim","year":"2005","unstructured":"Kim DJ, Yang WI, Choi SS et al (2005) Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest 127:755\u2013761","journal-title":"Chest"},{"key":"235_CR3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","volume":"94","author":"M Okumura","year":"2002","unstructured":"Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A (2002) The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94:624\u2013632","journal-title":"Cancer"},{"key":"235_CR4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","volume":"22","author":"P Strobel","year":"2004","unstructured":"Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, M\u00fcller-Hermelink HK, Marx A (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22:1501\u20131509","journal-title":"J Clin Oncol"},{"key":"235_CR5","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/ijc.25583","volume":"128","author":"SM Gadalla","year":"2011","unstructured":"Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Bj\u00f6rkholm M, Landgren O, Giaccone G (2011) A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 128:2688\u20132694","journal-title":"Int J Cancer"},{"key":"235_CR6","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","volume":"48","author":"A Masaoka","year":"1981","unstructured":"Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485\u20132492","journal-title":"Cancer"},{"key":"235_CR7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","volume":"95","author":"G Chen","year":"2002","unstructured":"Chen G, Marx A, Chen WH, Yong J, Puppe B, Stroebel P, Mueller-Hermelink HK (2002) New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 95:420\u2013429","journal-title":"Cancer"},{"key":"235_CR8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.athoracsur.2008.03.055","volume":"86","author":"E Davenport","year":"2008","unstructured":"Davenport E, Malthaner RA (2008) The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg 86:673\u2013684","journal-title":"Ann Thorac Surg"},{"key":"235_CR9","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0003-4975(03)01020-8","volume":"76","author":"F Venuta","year":"2003","unstructured":"Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, Ventura L, Osti MF, Francioni F, Coloni GF (2003) Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76:1866\u20131872","journal-title":"Ann Thorac Surg"},{"key":"235_CR10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jtcvs.2007.07.049","volume":"134","author":"J Huang","year":"2007","unstructured":"Huang J, Rizk NP, Travis WD, Seshan VE, Bains MS, Dycoco J, Downey RJ, Flores RM, Park BJ, Rusch VW (2007) Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 134:1477\u20131483","journal-title":"J Thorac Cardiovasc Surg"},{"key":"235_CR11","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","volume":"91","author":"PJ Loehrer Sr","year":"2001","unstructured":"Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, Livingston R, Johnson DH (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91:2010\u20132015","journal-title":"Cancer"},{"issue":"10 Suppl 4","key":"235_CR12","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1097\/JTO.0b013e3181f21129","volume":"5","author":"J Schmitt","year":"2010","unstructured":"Schmitt J, Loehrer PJ Sr (2010) The role of chemotherapy in advanced thymoma. J Thorac Oncol 5(10 Suppl 4):S357\u2013S360","journal-title":"J Thorac Oncol"},{"issue":"10 Suppl 4","key":"235_CR13","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1097\/JTO.0b013e3181f21114","volume":"5","author":"A Rajan","year":"2010","unstructured":"Rajan A, Giaccone G (2010) Targeted therapy for advanced thymic tumors. J Thorac Oncol 5(10 Suppl 4):S361\u2013S364","journal-title":"J Thorac Oncol"},{"key":"235_CR14","doi-asserted-by":"crossref","first-page":"383s","DOI":"10.1200\/JCO.2006.07.8162","volume":"24","author":"PJ Loehrer","year":"2006","unstructured":"Loehrer PJ, Yiannoutsos CT, Dropcho S et al (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma (abstract #7079). J Clin Oncol 24:383s","journal-title":"J Clin Oncol"},{"key":"235_CR15","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060\u20132065","journal-title":"J Clin Oncol"},{"issue":"10 Suppl 4","key":"235_CR16","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","volume":"5","author":"P Strobel","year":"2010","unstructured":"Strobel P, Hohenberger P, Marx A (2010) Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol 5(10 Suppl 4):S286\u2013S290","journal-title":"J Thorac Oncol"},{"key":"235_CR17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","volume":"36","author":"E Suzuki","year":"2006","unstructured":"Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y (2006) Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 36:351\u2013356","journal-title":"Jpn J Clin Oncol"},{"key":"235_CR18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","volume":"130","author":"JD Henley","year":"2004","unstructured":"Henley JD, Cummings OW, Loehrer PJ Sr (2004) Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130:222\u2013224","journal-title":"J Cancer Res Clin Oncol"},{"key":"235_CR19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","volume":"8","author":"G Farina","year":"2007","unstructured":"Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A (2007) Response of thymoma to cetuximab. Lancet Oncol 8:449\u2013450","journal-title":"Lancet Oncol"},{"key":"235_CR20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","volume":"12","author":"G Palmieri","year":"2007","unstructured":"Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L (2007) Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 12:757\u2013761","journal-title":"Front Biosci"},{"key":"235_CR21","doi-asserted-by":"crossref","first-page":"16s","DOI":"10.1200\/jco.2005.23.16_suppl.7068","volume":"23","author":"A Kurup","year":"2005","unstructured":"Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ (2005) Phase II study of gefitinib treatment in advanced thymic malignancies (abstract #7068). J Clin Oncol 23:16s","journal-title":"J Clin Oncol"},{"key":"235_CR22","doi-asserted-by":"crossref","unstructured":"Bedano P, Perkins S, Burns M et al. (2008) A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma (abstract #19087). J Clin Oncol 26s","DOI":"10.1200\/jco.2008.26.15_suppl.19087"},{"key":"235_CR23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","volume":"202","author":"CC Pan","year":"2004","unstructured":"Pan CC, Chen PC, Chiang H (2004) KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375\u2013381","journal-title":"J Pathol"},{"key":"235_CR24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","volume":"10","author":"G Giaccone","year":"2009","unstructured":"Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC (2009) Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 10:1270\u20131273","journal-title":"J Thorac Oncol"},{"key":"235_CR25","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Strobel","year":"2004","unstructured":"Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625\u20132626","journal-title":"N Engl J Med"},{"key":"235_CR26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","volume":"14","author":"NL Steele","year":"2008","unstructured":"Steele NL, Plumb JA, Vidal L, Tj\u00f8rnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804\u2013810","journal-title":"Clin Cancer Res"},{"key":"235_CR27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.thorsurg.2010.08.003","volume":"21","author":"A Rajan","year":"2011","unstructured":"Rajan A, Giaccone G (2011) Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 21:107\u2013114","journal-title":"Thorac Surg Clin"},{"key":"235_CR28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","volume":"190","author":"AM Cimpean","year":"2008","unstructured":"Cimpean AM, Raica M, Encica S, Cornea R, Bocan V (2008) Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 190:238\u2013245","journal-title":"Ann Anat"},{"key":"235_CR29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","volume":"124","author":"M Tomita","year":"2002","unstructured":"Tomita M, Matsuzaki Y, Edagawa M, Maeda M, Shimizu T, Hara M, Onitsuka T (2002) Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 124:493\u2013498","journal-title":"J Thorac Cardiovasc Surg"},{"key":"235_CR30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","volume":"103","author":"P Strobel","year":"2010","unstructured":"Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196\u2013200","journal-title":"Br J Cancer"},{"key":"235_CR31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","volume":"4","author":"G Bisagni","year":"2009","unstructured":"Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C (2009) Long lasting response to the multikinase inhibitor bay 43\u20139006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 4:773\u2013775","journal-title":"J Thorac Oncol"},{"key":"235_CR32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","volume":"26","author":"XF Li","year":"2009","unstructured":"Li XF, Chen Q, Huang WX, Ye YB (2009) Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 26:157\u2013160","journal-title":"Med Oncol"},{"key":"235_CR33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2010.09.011","volume":"71","author":"U Di\u015fel","year":"2011","unstructured":"Di\u015fel U, Oztuzcu S, Be\u015fen AA, Karadeniz C, K\u00f6se F, S\u00fcmb\u00fcl AT, Sezer A, Nursal GN, Abal\u0131 H, Ozy\u0131lkan O (2011) Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 71:109\u2013112","journal-title":"Lung Cancer"},{"key":"235_CR34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2613.2011.00777.x","volume":"92","author":"AM Cimpean","year":"2011","unstructured":"Cimpean AM, Ceau\u015fu R, Encic\u0103 S, Gaje PN, Ribatti D, Raica M (2011) Platelet-derived growth factor and platelet-derived growth factor receptor-\u03b1 expression in the normal human thymus and thymoma. Int J Exp Pathol 92:340\u2013344","journal-title":"Int J Exp Pathol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-012-0235-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0235-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T21:41:08Z","timestamp":1562276468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-012-0235-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,23]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1007\/s11523-012-0235-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,23]]}}}